2022 ANNUAL REPORT

Our Mission
The mission of the Lung Cancer Research Foundation (LCRF) is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment and cure of lung cancer.

Our Vision
Our vision is a world free of lung cancer.

LCRF History
The Lung Cancer Research Foundation has evolved over the years, but one thing remains the same: we are determined to create a world without lung cancer. Together, we can accomplish more than any one of us can alone.

2000
Steps for Breath, the first run-walk for lung cancer research and awareness in the country, is launched by Laurie Carson, a tireless advocate for increased funding for lung cancer research.

2001-04
Women Against Lung Cancer (WALC) is founded by Joan H. Schiller, MD. Joan's Legacy is founded in honor of Joan Scarangello McNeive.

2005-06
Laurie Carson expands her efforts across the country and creates the Lung Cancer Research Foundation (LCRF). Steps for Breath evolves into Strides for Life, one of LCRF's cornerstone events. WALC becomes the National Lung Cancer Partnership (NLCP) and hosts its first 5K Run/Walk, named Free to Breathe.

2007-08
NLCP begins offering free patient resources. The first Lung Cancer Action Summit is held in Chicago.

2009-12
Joan's Legacy officially becomes Uniting Against Lung Cancer (UALC) after joining forces with a number of like-minded partners across the country. NLCP reaches the milestone of contributing $1 million in research grants.

2013-14
LCRF and UALC join forces to make an even greater impact on lung cancer research by increasing the breadth and depth of their grant programs.

2015-16
LCRF and UALC become Free to Breathe. Free to Breathe partners with the Lung Cancer Mutation Consortium (LCMC), the largest national initiative testing lung cancer tumors and matching patients to therapies.

2017
NLCP becomes Free to Breathe. Free to Breathe merges with the Lung Cancer Mutation Consortium to make an even greater impact on closing the funding gap for lung cancer research.

2021
LCRF announces its goal of tripling its annual research investment by funding $45 million in direct lung cancer research through 444 grants by 2024. LCRF's nationwide walk and yoga events continue under the Free to Breathe name.
Our philosophy is simple: scientific discoveries lead to improved outcomes.

LCRF provides critical seed funding to the best and brightest investigators, helping establish proof of concept evidence to pave the way for follow-on funding. When it comes to research, we can accomplish more together than we can alone. Every grant our efforts make possible is an investment in the future.

**RESEARCH ROADMAP HIGHLIGHTS**

LCRF’s Scientific Executive Committee (SEC), a committee comprised of Scientific Advisory Board (SAB) members, developed recommendations for the foundation’s research program to address the needs of the lung cancer community and accelerate the pace of lung cancer research. Those recommendations include:

- Inclusion of patients in every aspect of LCRF’s research program, from determining funding areas, participating in grant review, education, awareness, and funding.

- Fund research in the areas of greatest need, with the greatest opportunity for impact: early detection, prevention, and diagnostics; understanding resistance; novel and innovative projects.

- Continue investment in basic and early career investigators and expand to include other levels of investigators as well as collaborative and team awards.

- Develop funding partnerships to drive impact and improve outcomes.

- Facilitate scientific knowledge and understanding through convening members of LCRF’s SAB with leading scientists, researchers, LCRF grantees, funders, and supporters by hosting meetings throughout the year.

**RESEARCH PRIORITIES FOR 2023**

To date, LCRF has funded 409 research grants, totaling over $42 million. By 2024, LCRF intends to fund a total of at least $45 million in direct lung cancer research. Priorities for funding include early detection, drug resistance, and innovation.

- **LCRF Leading Edge Grant**, seeking to ferret out novel ideas, approaches, methods, and techniques that promise to have a profound impact on lung cancer patients and their treatment teams.

- **LCRF Research Grant on Early Detection and Pre-Neoplasia in Lung Cancer**, which funds research projects that facilitate or advance the understanding and characterization of pre-neoplasia or approaches for early detection of lung cancer.

- **LCRF Research Grant on Understanding Resistance in Lung Cancer** supports projects that focus on characterizing, identifying, treating, overcoming, or preventing resistance to therapies in tumors harboring alterations in oncogenic drivers in non-small cell lung cancer cells, tissues, mouse models or patient tumors.

- **LCRF’s Minority Career Development Award (CDA) for Lung Cancer**, which aims to increase the number of highly skilled and trained researchers from groups that are historically underrepresented in academia, medicine, and leadership in lung cancer research.
**EARLY DETECTION & PRE-NEOPLASIA RESEARCH**

**MOHAMMAD SHAHROKH ESFAHANI, PhD**  
Stanford University  
*Noninvasive prediction of local recurrence in localized NSCLCs after CRT*

Circulating tumor DNA in patients being treated for NSCLC will be analyzed to look for biomarkers in the blood to identify markers of recurrence. The goal is to one day predict recurrence and strategize therapy based upon that prediction.

**TIM LAUTENSCHLAEGER, MD**  
Indiana University  
*24-hour urine based ctDNA analysis for early stage NSCLC detection*

The goal of this research is to evaluate urine as a better alternative to plasma in detecting circulating DNA from NSCLC. This could be valuable for diagnosing cancers as well as detecting recurrence.

**JAIME SCHNEIDER, MD, PhD**  
Massachusetts General Hospital  
*Metabolic reprogramming as a driver of resistance in ALK+ lung cancer*

This research aims to discover new ways to overcome resistance to ALK+ lung cancer therapy by targeting the metabolism. By identifying unique metabolic abnormalities that drive resistance, new treatments can be developed.

**ÁLVARO QUINTANAL VILLALONGA, PhD**  
Memorial Sloan-Kettering Cancer Center  
*Identifying epigenomic mechanisms of ALK TKI resistance*

This project will study ALK+ lung cancer therapy resistance, particularly those that are epigenetic – not mutations, but rather major shifts in the activity of genes in the cancer cell.

---

**ALK RESEARCH**

**Research is our true north.**

---

Getting the support I received from LCRF was a form of ‘life-support’ for an exciting new direction in my laboratory. Without that support, the project may have ended since I wouldn’t have had the resources to hire qualified scientists to do the work. With this support I eventually landed my first large NIH grant, and the research it supported is now published in a prominent cancer journal. I’m also very excited that several clinical trials will be launched based on the foundation of this project.”

*Chad Pecot, MD*  
UNC Lineberger Comprehensive Cancer Center  
2016 LCRF grantee
SMALL CELL LUNG CANCER RESEARCH

HUANHUA CHEN, PhD
The University of Chicago

A human pluripotent stem cell-based approach to metastasis of small cell lung cancer

This project plans to study primary small cell lung cancer and metastases. Understanding the process of SCLC metastases, and the cellular and molecular pathways involved, could generate ideas about better therapy for this type of cancer.

BINGNAN ZHANG, MD
University of Texas MD Anderson Cancer Center

Harnessing DLL3 as a CAR T target in small cell lung cancer

Dr. Zhang’s lab is studying a new immunotherapy approach for SCLC to overcome resistance. Laboratory tumor models will be used and the eventual goal is to bring this treatment into clinical trials.

AMANDA IRIS BRADLEY, PHD
Fred Hutchinson Cancer Center

Discovering genetic factors of MET Exon skipping and drug resistance in lung cancer

This project is taking a deeper dive into the different MET Exon 14 alterations to better understand how variants of MET cause drug resistance.

CARLA CONCEPCION, PHD
Columbia University Irving Medical Center

Targeting SMARCA4-deficient lung cancers

The SMARC4 gene is an indication of a poor prognosis in NSCLC. There is no treatment directed at SMARC4; however, SMARC2, which can also be present in SMARC4 deficient cancers, may be a target for treatment. The goal is to understand the interaction of SMARC4/2.

MINORITY CAREER DEVELOPMENT Awardees

AMANDA IRIS BRADLEY, PHD
Fred Hutchinson Cancer Center

Discovering genetic factors of MET Exon skipping and drug resistance in lung cancer

This project is taking a deeper dive into the different MET Exon 14 alterations to better understand how variants of MET cause drug resistance.

CARLA CONCEPCION, PHD
Columbia University Irving Medical Center

Targeting SMARCA4-deficient lung cancers

The SMARC4 gene is an indication of a poor prognosis in NSCLC. There is no treatment directed at SMARC4; however, SMARC2, which can also be present in SMARC4 deficient cancers, may be a target for treatment. The goal is to understand the interaction of SMARC4/2.

KRAS RESEARCH

MATTHEW GUMBLETON, MD, PhD
Massachusetts General Hospital

KRAS inhibitors for the treatment of invasive mucinous adenocarcinoma

Invasive mucinous adenocarcinoma (IMA) of the lung is an aggressive subtype of lung cancer. Since IMA is primarily KRAS+, this research will study the role of KRAS inhibitors to improve treatment for IMA of the lung.

“LRCF funding was instrumental in allowing me to complete and publish the project I was working on at the time. The project has fostered cross-institutional collaborations and a clinical trial. It provided support at a critical juncture so I can continue doing research. Now it serves as a springboard for me to compete for Federal funding with the results and publications I generated.”

Victoria Wang, MD, PhD
University of California, San Francisco Two-time LCRF grantee
MET RESEARCH

TIMOTHY BURNS, MD, PhD
University of Pittsburgh

**Targeting glycolysis in MET altered lung cancer brain metastases**

This project will study the metabolic pathways in MET-altered lung cancer, especially in brain metastases (BM). The abnormalities in metabolism will be defined and metabolic inhibitors will be used to target these abnormalities. This could lead to new therapies for patients with MET-altered lung cancer.

EMILIANO COCCO, PhD
Miller School of Medicine, University of Miami

**Exploring novel therapeutic options to target MET-driven lung cancers**

*2022 William C. Rippe Award for Distinguished Research in Lung Cancer*

This project has two goals. The first one is to study a new antibody-drug conjugate in MET-altered lung cancer models. The researcher also plans to evaluate MET mutations that occur as a resistance mechanism. Knowing which mutations are driving resistance could potentially direct treatment.

XIUNING LE, MD, PhD
University of Texas MD Anderson Cancer Center

**Optimization of MET-CAR-T/NK cell-based therapies for MET Exon 14 skipping NSCLC**

This project plans to engineer novel immunotherapeutic approaches to target MET-altered lung cancer. The researcher will use a combination of cell therapy and other MET inhibitors to enhance their effect.

EGFR RESEARCH

SWARNALI ACHARYYA, PhD
Columbia University Medical Center

**Drugging the S100A9-Retinoic acid pathway: companion biomarker and therapy**

*2022 James B. Dougherty, MD Award for Scientific Merit*

This research will study a new pathway as a new target that when inhibited could prevent and/or treat brain metastases. The potential benefit could also extend to patients with leptomeningeal disease.

LUKE HOEPPNER, PhD
University of Minnesota, Twin Cities

**Predictive biomarkers and new therapeutic strategies to prevent EGFR TKI-refractory lung cancer progression**

This project is attempting to understand how lung cancer cells evade EGFR targeted therapy and aims to develop new innovative therapies to predict and prevent the emergence of resistance and disease progression.

JONATHAN OSTREM, MD, PhD
University of California, San Francisco

**Enhancing the precision of targeted therapies for EGFR-mutant lung cancer**

The goal of this research is to develop a new therapy for EGFR positive lung cancer that would enhance effective cancer killing activity while limiting toxicity to healthy tissue in the body. The initial focus will be on EGFR Exon 20 tumors but eventually could be applied to other targeted therapies.
The Lung Cancer Mutation Consortium (LCMC) is an association of more than 20 U.S. cancer centers focused on understanding the genetic changes that underlie lung cancers. Through the testing of tumor tissues to uncover genetic changes, LCMC investigators match patients with targeted drugs and clinical trials designed to change the practice of thoracic oncology. Ultimately, the LCMC seeks to improve outcomes in patients whose tumors harbor oncogenic drivers. The Lung Cancer Research Foundation acts as facilitator for the LCMC, coordinating and supporting its activities.

The LCMC is a unique model that brings together advocacy, academic, and industry partners in a collaborative setting. This strategy streamlines research efforts, cuts cost and delays, facilitates connections with the lung cancer and advocacy communities, and brings us closer to the goal of precision medicine where therapies are matched to the specific needs of each person with lung cancer.

Current Study: LCMC4

LCRF LEADER Neoadjuvant Screening Trial

LCMC4 Evaluation of Actionable Drivers in Early-Stage Lung Cancer

The current LCMC study, the LCRF LEADER Neoadjuvant Screening Trial, is the fourth study conducted through the consortium and is a collaborative effort involving numerous academic study sites and pharmaceutical supporters.

Utilizing an umbrella trial design, the primary purpose of this testing is to determine the presence of 10 oncogenic drivers (mutations in EGFR, BRAFV600E, MET exon 14, and HER2, rearrangements in ALK, RET, NTRK, and ROS1, and amplification of MET and HER2) in 1,000 patients that can serve as targets, making patients eligible for upcoming targeted neoadjuvant therapy trials. The goal is to use this information from the screening process to select the optimal neoadjuvant therapy, and wherever possible, enroll patients onto separate neoadjuvant therapy trials with genomically matched treatments or other appropriate trials if no actionable driver mutation is detected. The LCMC4 screening study, together with matched industry-sponsored therapeutic trials, will provide critical data for informing treatment decisions in the neoadjuvant setting.

This study will allow for inspection of tumors after neoadjuvant treatment to understand what oncogenic drivers remain that made the tumor resistant to that particular therapy.

LCMC4 LEADER Trial Participating Sites

The LCMC4 LEADER trial will include participation from sites and investigators across the oncology community.

**Participating sites**
- Memorial Sloan Kettering Cancer Center
- University of Texas MD Anderson Cancer Center
- Vanderbilt University
- Dana Farber Cancer Institute
- Dartmouth-Hitchcock
- Karmanos Cancer Center
- Moffitt Cancer Center
- NYU
- Ohio State
- Sarah Cannon Cancer Center
- St. Josephs Hospital Center for Cancer Prevention and Treatment
- UCLA
- University of California-Davis
- University of Colorado
- University of Miami
- University of Michigan
- University of Missouri
- University of Washington
- USC Norris Cancer Center
- Virginia Cancer Specialists
- Washington University
- Yale University

**Prospective participating sites**
- Case Comprehensive Cancer Center
- Cedars-Sinai
- City of Hope Cancer Center
- Columbia University
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

Begun in 2008, the first LCMC study was a multi-institutional program for investigating the frequency of selected oncogenic drivers in advanced lung cancers.

Using the results to treat participants with targeted therapies, either as part of standard clinical care or on investigational protocols, the study demonstrated the feasibility of widespread implementation of mutational profiling in the clinical care of patients with lung cancer.

With 14 institutions participating and over 1,000 patients enrolled, the study was one of the largest of its kind to address the many challenges that arise in the course of molecular testing of solid tumors for therapeutic decision-making.

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations

Building on the initial accrual of 1,000 patient samples from the first study, the second LCMC trial accrued an additional 1,000 patients. This cohort, with stage IV lung cancers whose tissue samples were tested with a larger panel of molecular targets, received approved medications or were again enrolled into “matched” therapeutic trials.

These two studies demonstrated that oncogenic drivers were detected in more than half of patients with lung adenocarcinomas and that treating these patients with targeted therapies improved survival. The LCMC2 trial also established that secondary genetic alterations that are not drivers (e.g. p53) could influence the outcomes of patients receiving targeted therapy.

Ultimately, these studies led to major changes in guidelines for biomarker testing including advocating for routine next generation sequencing at diagnosis.

A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable NCLC

With success in patients with stage IV disease, the LCMC3 study shifted attention to early stage lung cancers. For the first time, the study scope included thoracic surgery leaders from member institutions, recognizing their central role in care and research in the perioperative setting.

With enrollment begun in 2017 and completed in 2020, LCMC3 was designed as a neoadjuvant and adjuvant trial of immune checkpoint blockade for stage IB-IIIA non-small cell lung cancer.

The goals of this study included providing early stage patients with a new treatment option and leveraging the LCMC’s expertise in multicenter studies to address questions about the biology of response and resistance to immunotherapeutics.

For additional information, contact LungCancerMutationConsortium@LCRF.org

Lung Cancer Mutation Consortium
LCRF.org/LCMC

©2021
A strong community is a natural outcome when people share a sense of purpose.

LCRF’s fundraising events are not just a way for individuals to impact life-saving research; they also show people affected by lung cancer that they are not alone. Participants tell us they experience an outpouring of compassion and kindness at a whole new level.

LCRF hosts several different types of gatherings where attendees can fundraise and donate towards research grants. At the heart of every one is a focus on what lung cancer research means for patients and families. Learn more at LCRF.org/getinvolved.

Free to Breathe Walk

The Free to Breathe Walk is a grassroots fundraising event bringing people together in several cities across the nation. Those unable to attend an in-person walk can join the Free to Breathe Anywhere Walk and walk at the time and place of their choosing.

Butterfly imagery abounds, representing hope, strength, metamorphosis, and resilience. Different colored butterflies represent participants’ connection to lung cancer and provide a way for people to identify one another. Opening ceremonies are elevated by a mission moment recognizing survivors, loved ones, supporters, and those who have lost someone to lung cancer. A local survivor is invited to speak at each walk.

Free to Breathe Your Way

Free to Breathe Your Way fundraising encompasses all sorts of individual events – golf outings, picnics, concerts, and more. LCRF provides support and information that doubly serves to raise awareness about lung cancer.

Evening of Innovation Gala

The Evening of Innovation Gala is LCRF’s premiere event celebrating scientific discovery and honoring the work of research luminaries.

This black-tie event raised more than $650,000 at its inaugural in 2022, which honored Dr. Brendon Stiles and Dr. David Hidalgo. Patient speakers headline the gala. This year’s honoree is Dr. Katerina Politi.

A looping presentation features every patient in attendance, highlighting them with a photo and quotation. The presentation also includes caregivers and people who had lost someone close to them. Messages of hope and congratulations appear alongside tributes to the honorees in a keepsake gala journal, which also is shared digitally.
LCRF educates and supports the lung cancer community through online and in-person programming, our Lung Cancer Support Line, and printed materials written especially for patients and caregivers.

Our #TogetherSeparately educational webinar series was developed in response to the 2020 pandemic. The series continues to be popular, highlighting topics of interest with a variety of guest experts.

LCRF hosts a Facebook group, the #TogetherSeparately Lung Cancer Support Community, which offers a place for patients and caregivers to continue their conversations.

Learn more about how we support the lung cancer patient community by visiting LCRF.org/patients.

**In-person events**

LCRF hosts a variety of in-person educational programs and community gatherings. Regardless of the event type, they all have a common goal: to create a connected “second family” among those impacted by lung cancer, with a focus on what lung cancer research means for patients and families. In 2023, LCRF will expand its reach to the Chicago, New York City, and Washington, DC metropolitan areas.

**Educational materials**

To empower patients to play an active role in their treatment decisions, LCRF offers relevant, accurate, and up-to-date education in layperson-friendly language. These evidence based materials are developed in conjunction with LCRF’s Education + Engagement Committee and are offered free of charge. In 2023, we plan to overhaul our immunotherapy booklet, adapt key pieces into Spanish, and develop new pieces on specific mutations.

**Know Your Risk Español**

Expanding on the success of LCRF’s Know Your Risk guide for Black Americans, this program will provide Spanish-speaking Americans vital information on lung cancer and its subtypes, screening, risk factors, early detection and diagnosis, comprehensive biomarker testing, clinical trials, and accessing care.

Educational components include a Spanish-language documentary video and key printed materials translated into Spanish.

**Education + Engagement Committee**

This newly-formed group of clinicians, researchers, patients, caregivers and advocates is tasked with ensuring that LCRF provides educational content that is relevant, helpful, and meets the needs of the lung cancer community. In addition, the committee ensures these resources are readily available to inform and empower individuals on their lung cancer journey.
LCRF provides up-to-date, credible information on diagnosis, treatment, and what to expect from treatment through our free educational materials – including tools to help facilitate discussions between patients and their healthcare teams.

Our goal is to provide relevant, accurate information in layperson-friendly language in order to empower patients to play an active role in their treatment decisions.

These patient education materials are evidence based and developed in conjunction with LCRF’s Education + Engagement Committee, comprised of oncologists, researchers, oncology nurses, social workers, patients, caregivers, and advocates.

More than 125,000 pieces were distributed in 2022.

Materials are available in both digital download and print format. Shipping is free to addresses in the United States.

Visit LCRF.org/resources for a complete list of materials available for order.

- **Living With Lung Cancer**
  - Spanish translation in progress
  - our flagship resource

- **Understanding Squamous Cell Lung Cancer**

- **Understanding Small Cell Lung Cancer**

- **Caregiving for a Loved One with Lung Cancer**

- **Immunotherapy for the Treatment of Lung Cancer**
  - major revision and Spanish translation coming in 2023

- **My Lung Cancer Care Plan**
  - recently updated; loose pages for tracking appointments can be added to a 3-ring binder

- **Comprehensive Biomarker Testing for Lung Cancer**
  - recently updated; 1-page quick guide also available

- **Understanding Clinical Trials for Lung Cancer**
  - recently updated; 1-page quick guide also available
# BOARD OF DIRECTORS

**EXECUTIVE COMMITTEE**

**BOARD CHAIR**

<table>
<thead>
<tr>
<th>Board Chair</th>
<th>Raymond E. Chalmé</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CEO &amp; Partner, Broad Street Development LLC</td>
</tr>
</tbody>
</table>

**BOARD VICE CHAIR**

<table>
<thead>
<tr>
<th>Board Vice Chair</th>
<th>Brendon M. Stiles, MD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Chief, Division of Thoracic Surgery and Surgical Oncology</td>
</tr>
<tr>
<td></td>
<td>Associate Director, Surgical Services, Montefiore-Einstein Cancer Center</td>
</tr>
</tbody>
</table>

**TREASURER**

<table>
<thead>
<tr>
<th>Treasurer</th>
<th>Aaron M. Tighe</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Managing Director, Credit Suisse</td>
</tr>
<tr>
<td></td>
<td>Co-Chair, Guggenheim Museum Photography Acquisition Committee</td>
</tr>
</tbody>
</table>

**CHAIR, CORPORATE DEVELOPMENT COMMITTEE**

<table>
<thead>
<tr>
<th>Chair</th>
<th>Bruce Dunbar</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Coppertop Media</td>
</tr>
</tbody>
</table>

**CHAIR, SCIENTIFIC ADVISORY BOARD**

<table>
<thead>
<tr>
<th>Chair</th>
<th>Katerina Politi, PhD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Associate Professor of Pathology and Internal Medicine, Yale School of Medicine</td>
</tr>
</tbody>
</table>

**BOARD LIAISON, EDUCATION + ENGAGEMENT COMMITTEE**

<table>
<thead>
<tr>
<th>Engagement Chair</th>
<th>Joan Schiller, MD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Adjunct Professor, Department of Medicine, University of Virginia</td>
</tr>
</tbody>
</table>

**CHAIR, CORPORATE DEVELOPMENT COMMITTEE**

<table>
<thead>
<tr>
<th>Chair</th>
<th>Bruce Dunbar</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Coppertop Media</td>
</tr>
</tbody>
</table>

**BOARD MEMBERS**

**Raymond E. Chalmé**

- CEO & Partner, Broad Street Development LLC

**Matt Cipriani**

- 3C/Cipriani Construction Consulting

**Peter M. Fry**

- Managing Director, Head of Alternative Equities, SVB Leerink, LLC

**Jill Furman**

- Theater producer

**Scott Morris**

- Creative Artists Agency

**Mary Ann Tighe**

- CEO, CBRE

**Rose Ann Weinstein**

- Fashion designer

**Colleen Connor Ziegler**

- Patient advocate

View more detailed biographies at [LCRF.org/board](http://LCRF.org/board).

Updated February 2023
MEMBERS

**CHIARA AMBROGIO, PHD**
Associate Professor, University of Torino

**ALICE BERGER, PHD**
Assistant Member, Human Biology Division
Fred Hutchinson Cancer Research Center
Assistant Professor, Genome Sciences
University of Washington

**JULIE R. BRAHMER, MD**
Director, Thoracic Oncology Program
Interim Director, Sidney Kimmel Cancer Center
at Johns Hopkins Bayview
Associate Professor of Oncology
Johns Hopkins University Medical School

**DAVID P. CARBONE, MD, PHD**
Past-President, International Association for
the Study of Lung Cancer (IASLC)
Barbara J. Bonner Chair in Lung Cancer Research
Professor of Medicine
The Ohio State University Wexner Medical Center
Comprehensive Cancer Center

**IBAIYI DAGOGO-JACK, MD**
Assistant Professor of Medicine
Harvard Medical School
Thoracic Oncologist
Massachusetts General Hospital

**JESSICA DONINGTON, MD, MSCR**
Professor and Chief General Thoracic Surgery
University of Chicago School of Medicine

**ALEXANDER DRILON, MD**
Chief, Early Drug Development Service
Memorial Sloan Kettering Cancer Center

**STEVEN M. DUBINETT, MD**
Professor and Chief, Division of Pulmonary and Critical Care Medicine
Director, UCLA Lung Cancer Research Program
Senior Associate Dean for Clinical and Translational Science
Associate Vice Chancellor for Research
David Geffen School of Medicine
University of California, Los Angeles

**LORETTA ERHUNMWUNSEE, MD**
Thoracic Surgeon, Assistant Professor, Division of Thoracic Surgery
Assistant Professor, Division of Health Equities
City of Hope Cancer Center

**SARAH GOLDBERG, MD, MPH**
Associate Professor of Internal Medicine (Medical Oncology)
Associate Director, Hematology/Oncology Fellowship Program
Research Director, Center for Thoracic Cancers
Yale School of Medicine

**ERIC HAURA, MD**
Director, Lung Cancer Center of Excellence
Program Leader, Chemical Biology and Molecular Medicine
Senior Member, Department of Thoracic Oncology
Professor of Medicine & Oncologic Sciences, University of Florida
H. Lee Moffitt Cancer Center

**ROY S. HERBST, MD, PHD**
Ensign Professor of Medicine
Chief of Medical Oncology
Associate Director for Translational Research
Yale Comprehensive Cancer Center | Yale School of Medicine
Smiilow Cancer Hospital

**JOHN V. HEYMACH, MD, PHD**
Associate Professor, Thoracic/Head and Neck Medical Oncology
Chief, Section of Thoracic Medical Oncology
The University of Texas MD Anderson Cancer Center

**DONALD W. KUFE, MD**
Distinguished Physician
Professor of Medicine
Leader, Developmental Therapeutics Program
Dana-Farber/Harvard Cancer Center | Harvard Medical School

**MARC LADANYI, MD**
Chief, Molecular Diagnostics Service
William J. Ruane Chair in Molecular Oncology
Memorial Sloan-Kettering Cancer Center

**WILLIAM LOCKWOOD, PHD**
Senior Scientist
BC Cancer Research, Integrative Oncology

**CHRISTINE M. LOVLY, MD, PHD**
Assistant Professor of Medicine, Division of Hematology-Oncology
Assistant Professor of Cancer Biology
Vanderbilt University School of Medicine
Vanderbilt Ingram Cancer Center

**MATTHEW L. MEYERSON, MD, PHD**
American Cancer Society Research Professor
Professor of Pathology, Harvard Medical School and Dana-Farber Cancer Institute
Director, Center for Cancer Genome Discovery, DFCI
Institute Member, Broad Institute of MIT and Harvard
Dana-Farber Cancer Institute | Harvard Medical School

(continued)
JOHN MINNA, MD*  
Professor & Director  
Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology  
Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research  
Hamon Center for Therapeutic Oncology Research  
UT Southwestern Medical Center  

KATHRYN O’DONNELL, PHD  
Associate Professor, Molecular Biology  
UT Southwestern Medical Center  

TRUDY G. OLIVER, BSC (HONS), PHD*  
PROFESSOR OF HEMATOLOGY AND MEDICAL ONCOLOGY  
DIRECTOR OF MEDICAL ONCOLOGY  
ROBERTO C. GOIZUETA CHAIR IN CANCER RESEARCH  
DEPUTY DIRECTOR, WINSHIP CANCER INSTITUTE  
ASSISTANT DEAN FOR CANCER  
EMORY UNIVERSITY SCHOOL OF MEDICINE  

SURESH S. RAMALINGAM, MD  
Professor, Department of Hematology and Medical Oncology  
Roberto C. Goizueta Distinguished Chair for Cancer Research  
Emory University School of Medicine  
Executive Director, Winship Cancer Institute of Emory University  
Associate Vice President for Cancer, Woodruff Health Sciences Center  

KAREN RECKAMP, MD, MS  
Professor, Division of Medical Oncology  
Associate Director for Clinical Research  
Director of Medical Oncology, Women’s Guild Lung Institute  
Cedars-Sinai  

HILARY ROBBINS, PHD, MPH*  
Research Scientist, Epidemiology  
International Agency for Research on Cancer  

JACK A. ROTH, MD  
Chief, Section of Thoracic Molecular Oncology  
Professor, Department of Thoracic and Cardiovascular Surgery  
The University of Texas MD Anderson Cancer Center  

CHARLES M. RUDIN, MD, PHD  
Chief of Thoracic Oncology Service  
Co-Director, Druckenmiller Center for Lung Cancer Research  
Sylvia Hassenfeld Chair in Lung Cancer Research  
Memorial Sloan Kettering Cancer Center  

JULIEN SAGE, PHD*  
Professor of Pediatric Cancer and Genetics  
Stanford University  

JOAN H. SCHILLER, MD  
Professor, Department of Medicine  
Section of Hematology Oncology  
University of Virginia  

ANN G. SCHWARTZ, PHD, MPH  
Deputy Center Director  
Karmanos Cancer Institute  
Professor and Associate Chair Department of Oncology  
Wayne State University School of Medicine  

JILL SIEGFRIED, PHD  
Professor and Head, Department of Pharmacology  
Frederick and Alice Stark Endowed Chair  
Associate Director for Translation, Masonic Cancer Center  
University of Minnesota Medical School  

RAFFAELLA SORDELLA, PHD*  
Associate Professor  
Cold Spring Harbor Laboratory  

DAVID SPIGEL, MD  
Chief Scientific Officer  
Sarah Cannon Research Institute  

EVA SZABO, MD  
Chief, Lung and Upper Aerodigestive Cancer Group  
Division of Cancer Prevention  
National Cancer Institute, NIH  

DIANE TSENG, MD, PHD*  
Assistant Professor, Clinical Research Division  
Fred Hutchinson Cancer Center  

RALPH R. WEICHSELBAUM, MD*  
Daniel K. Ludwig Distinguished Service Professor and Chairman  
Department of Radiation and Cellular Oncology  
University of Chicago Medical Center  

ROBERT A. WINN, MD sec  
Director & Lipman Chair in Oncology, VCU Massey Cancer Center  
Senior Associate Dean for Cancer Innovation  
Professor of Pulmonary Disease and Critical Care Medicine  
VCU School Of Medicine  

KWOK-KIN WONG, MD, PHD**  
Anne Murnick Cogan and David H. Cogan Professor of Oncology, Department of Medicine  
Director, Division of Hematology and Medical Oncology  
Laura & Isaac Perlmutter Cancer Center  
NYU Langone Medical Center  

COLLEEN CONNER ZIEGLER sec  
Member, LCRF Board of Directors  
Lung cancer patient advocate

* indicates LCRF grant recipients  
sec Scientific Executive Committee  

UPDATED MARCH 2023
2022 Financials

To view the Lung Cancer Research Foundation’s previous audited financial statements and Form 990, please refer to our web page: LCRF.org/financials.

FUNDING SOURCES
Contributions and grants $4,941,518
Event revenue $1,522,677
Other $28,829
Total $6,493,024

YOUR DOLLARS AT WORK
Direct research $3,022,712
Program services $2,546,648
Fundraising $567,237
Management and general $279,307
Total $6,415,904

NET ASSETS
Total net assets Dec 31, 2022 $3,585,118